CERo Therapeutics Holdings, Inc. Warrants (CEROW)
Company News
CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO
CERo Therapeutics Holdings, Inc. (CERO) has appointed Chris Ehrlich as its new CEO. The company is advancing the development of next-generation engineered T cell therapeutics for cancer treatment, with plans to initiate clinical trials for its lead product candidate CER-1236 in early 2025 for acute myeloid leukemia (AML).